All In Biotech

Drug Trial Radar · NCT01207414

Switching to Iloperidone From Other Antipsychotics in Schizophrenia

A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24 mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole

Last checked: Nov 20, 2026Latest source record: Mar 15, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 501 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

501

Actual

Start

Aug 2010

Primary completion

Jan 2012

Study completion Jan 2012

Sponsor

Lead sponsor
NovartisNovartis (NVS)
Sponsor type
Industry
First posted
Sep 22, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate the clinical outcome of two switching strategies to iloperidone treatment in adult subjects with schizophrenia who require a change in their current antipsychotic treatment of risperidone, olanzapine, or aripiprazole due to suboptimal efficacy and/or safety/tolerability reasons.

Conditions

  • Schizophrenia

Interventions

  • iloperidoneDrug

    Iloperidone tablets supplied at doses of 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg to achieve a target dose of 12-24 mg/day for 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Integrated Clinical Global Impression of Change (I-CGI-C) at Week 12Time frame: Week 12

Locations

59 sites in 1 country. Site status is shown where the registry gives one.

  • Birmingham Psychiatry Pharmaceutical Studies, Inc.

    Birmingham, Alabama

  • Comprehensive Neuroscience

    Cerritos, California

  • ATP Clinical Research Center, Inc.

    Costa Mesa, California

  • Collaborative Neuroscience Network

    Garden Grove, California

  • Apostle Clinical Trials, Inc.

    Long Beach, California

  • Pacific Health Systems

    National City, California

  • Pacific Research Partners

    Oakland, California

  • Excell Research, Inc.

    Oceanside, California

  • University of California, Irvine

    Orange, California

  • CNRI San Diego

    San Diego, California

  • Affiliated Research Institute

    San Diego, California

  • Artemis Institute for Clinical Research

    San Diego, California

  • Neuropsychiatric Research Center of Orange County

    Santa Ana, California

  • Viking Clinical Research

    Temecula, California

  • Collaborative Neuroscience

    Torrance, California

  • The Hospital of Central Connecticut

    New Britain, Connecticut

  • Comprenhensive Neuroscience

    Washington D.C., District of Columbia

  • Amit K. Vijapura MD & Associates

    Jacksonville, Florida

  • Scientific Clinical Research

    North Miami, Florida

  • Atlanta Center for Medical Research

    Atlanta, Georgia

  • Comprehensive Neuroscience

    Atlanta, Georgia

  • Northwest Behavioral Research Center

    Marietta, Georgia

  • Carman Research

    Smyrna, Georgia

  • Institute for Behavioral Medicine

    Smyrna, Georgia

  • Alexian Brothers Center for Mental Health

    Arlington Heights, Illinois

  • Rush University Medical Center, Treatment Research Center

    Chicago, Illinois

  • University of Illinois at Chicago

    Chicago, Illinois

  • AMR - Baber Research, Inc.

    Naperville, Illinois

  • Midwest Center for Neurobehavioral Medicine

    Oakbrook Terrace, Illinois

  • Louisiana Clinical Research

    Shreveport, Louisiana

  • Neurobehavioral Medicine Group, Clinical Trials Division

    Bloomfield Hills, Michigan

  • Rochester Center for Behavioral Medicine

    Rochester Hills, Michigan

  • Precise Research Centers

    Flowood, Mississippi

  • St. Charles Psychiatric Associates - Midwest Research Group

    Saint Charles, Missouri

  • Center for Emotional Fitness

    Cherry Hill, New Jersey

  • CRI World Wide Clinical Research Company

    Willingboro, New Jersey

  • Albuquerque Neuroscience

    Albuquerque, New Mexico

  • Neurobehavioral Research

    Cedarhurst, New York

  • Comprehensive Neuroscience

    Fresh Meadows, New York

  • Division of Psychiatry Research - Zucker Hills Hospital

    Glen Oaks, New York

Showing 40 of 59 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.